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Abstract
Signal transducer and activator of transcription 6 (STAT6) transmits signals from cytokines IL-4 
and IL-13 and is activated in allergic airway disease. We are developing phosphopeptide mimetics 
targeting the SH2 domain of STAT6 to block recruitment to phosphotyrosine residues on IL-4 or 
IL-13 receptors and subsequent Tyr641 phosphorylation to inhibit the expression of genes 
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contributing to asthma. Structure–affinity relationship studies showed that phosphopeptides based 
on Tyr631 from IL-4Rα bind with weak affinity to STAT6, whereas replacing the pY+3 residue 
with simple aryl and alkyl amides resulted in affinities in the mid to low nM range. A set of 
phosphatase-stable, cell-permeable prodrug analogues inhibited cytokine-stimulated STAT6 
phosphorylation in both Beas-2B human airway cells and primary mouse T-lymphocytes at 
concentrations as low as 100 nM. IL-13-stimulated expression of CCL26 (eotaxin-3) was inhibited 
in a dose-dependent manner, demonstrating that targeting the SH2 domain blocks both 
phosphorylation and transcriptional activity of STAT6.
Graphical abstract
INTRODUCTION
Signal transducer and activator of transcription 6 (STAT6) transmits signals from cytokines 
interleukin 4 (IL-4) and IL-13.1–3 Under normal conditions, STAT6 is required for helper T 
cell type 2 (Th2) development in the context of allergic inflammatory responses and is 
hypothesized to contribute to the polarization of macrophages to the M2 phenotype.4 Upon 
receptor binding, both IL-4 and IL-13 induce phosphorylation of tyrosine residues located 
within the intracellular region of IL-4Rα (Figure 1). STAT6, via its SH2 domain, is 
recruited to these phosphotyrosine residues and is itself phosphorylated on Tyr641 by 
associated Janus kinases 1 and 3 (JAK1 and JAK3). Tyrosine phosphorylated STAT6 
(pSTAT6) then dimerizes via reciprocal SH2 domain-pTyr interactions, allowing it to 
translocate to the nucleus, where it participates in the transcription of allergy-related genes. 
The IL-4/IL-13/JAK/STAT6 pathway plays a key role in asthma pathogenesis.1,2 Patients 
have elevated levels of IL-4 and IL-13 in their airways and elevated pSTAT6 levels have 
been found in bronchial epithelium.5 Stat6 knockout mice do not develop airway 
hyperresponsiveness (AHR) or lung pathology associated with asthma.6
Intervention in the IL-4/IL-13/JAK/STAT6 pathway at several points for the treatment of 
asthma is being actively pursued by the pharmaceutical industry and academic 
laboratories.1,2 These include small molecules without described inhibitory mechanisms,7–12 
non-SH2 domain directed dimerization inhibitors,13 JAK inhibitors,14,15 siRNA,6 decoy 
oligonucleotides,16 phosphopeptides targeting the SH2 domain of STAT6,17–19 antibodies 
targeting IL-13,20 and antibodies targeting IL-4Rα.20–22 Our approach is to target the SH2 
domain of STAT6 with small molecule peptidomimetics to block recruitment to IL-4Rα, 
thereby preventing subsequent phosphorylation of Tyr641 by JAKs, dimerization, 
translocation to the nucleus, and transcription of genes, leading to airway inflammation. 
Proof of principle that steric blockade of the SH2 domain of STAT6 prevents recruitment to 
IL-4Rα, phosphorylation of Tyr641, and subsequent transcriptional activity leading to 
asthma symptoms has been demonstrated using phosphopeptides derived from Tyr631 of 
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IL-4Rα, the docking site for STAT6,18 and Tyr641 of STAT6,17,19 with cell penetration 
peptides attached.
To the best of our knowledge, no systematic structure–affinity or structure–activity studies of 
phosphopeptide ligands of the SH2 domain of STAT6 have appeared in the literature. In this 
communication, we report truncation and amino acid substitutions on a phosphopeptide 
based on the sequence surrounding Tyr631 of IL-4Rα to gain an understanding of the 
determinants for binding affinity that could be used in the design of STAT6 antagonists. In 
parallel, a structure–affinity study of phosphate analogues of a phosphopeptide mimic 
reported in the patent literature23,24 was also conducted. A molecular docking study 
illustrated key intramolecular interactions that help explain the higher affinity of the mimics 
compared to the receptor-derived peptide ligand. Bis-POM prodrugs of phosphatase-stable 
phosphonodifluoromethyl analogues of a set of the new inhibitors provided a structure–
activity relationship for inhibition of IL-4 and IL-13 stimulated phosphorylation of Tyr641in 
intact human airway epithelial cells. Several inhibitors induced significant inhibition at 100–
500 nM in this cell line as well as in a human breast cancer cell line and primary murine T 
lymphocytes. Expression of the downstream target, CCL26 (eotaxin-3) was inhibited, which 
demonstrates that, in addition to inhibition of Tyr641 phosphorylation, this class of 
compounds blocks transcriptional activity of STAT6.
RESULTS
Affinity of Phosphopeptides for STAT6
To understand basic requirements for phosphopeptide binding to the SH2 domain and to 
possibly find a lead for peptide mimetic development, we screened a series of peptides based 
on the STAT6 docking site of IL-4Rα, Tyr 631. As SH2 domains typically recognize 
phosphotyrosine and two to four residues on its C-terminal side,25,26 we prepared a series of 
N-terminal pTyr phosphopeptides. The fluorescence polarization assay of Wu et al.27 was 
used to monitor affinity. A construct consisting of an N-terminal His6 tag, the coiled-coil 
domain, the DNA binding domain, the linker domain, and the SH2 domain of STAT6 was 
cloned, expressed in Escherichia coli, and purified by nickel IMAC chromatography for use 
in these studies. Overall, the peptides displayed rather weak avidity to STAT6 with IC50 
values ranging from 2–6 µM (Table 1). Peptide length was important as affinities decreased 
from the octapeptide 1 (IC50 = 2 µM) to the tetrapeptide 5 (IC50 = 6 µM). Substitution of 
alanine for lysine at position pY+1 resulted in a significant reduction in affinity, while other 
amino acids such as tertiary leucine (Tle) and norleucine (Nle) were equipotent to lysine (7–
9, Table 2). Thus, this position requires at the minimum β substitution and the ε-amino 
group of lysine does not provide interaction energy. A small screen of N-terminal 
hydrophobic appendages showed no significant effect on affinity (10–13, Table 2), and 
therefore further elaboration of this position was not pursued. Replacement of pTyr with 
constrained surrogates 4-phosphoryloxycinnamide (14) and 7-phosphoryloxyindole-2-
caboxamide (15), which provided notable improvement in affinity for phosphopeptide 
inhibitors of STAT3,28 provided no significant increase in binding to STAT6 in this series of 
peptides (Table 3). Interestingly, incorporation of 7-phosphoryloxybenzofuran-2-
caboxamide (16) led to a substantial decrease in affinity. This suggests that the NH group of 
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the indole may be close to a hydrogen bond acceptor such as a carbonyl oxygen which 
would repel the oxygen atom of the benzofuran. In summary, phosphopeptides based on 
Tyr631 of the IL-4Rα displayed low affinity for STAT6 protein and were not useful as leads 
for inhibitor development.
In the late1990s, researchers from Tularik, Inc., recognized the potential of inhibition of 
STAT6 for the treatment of allergic airway disease and developed phosphopeptide mimics 
targeting the SH2 domain.23,24 Structure–affinity studies were reported, but only one 
compound with the potential to inhibit pSTAT6 in intact cells was described in the patents 
(17, Figure 2). Compound 17 is a phosphopeptide mimic in which phosphotyrosine is 
replaced by the conformationally constrained cinnamate unit. Stability to phosphatases was 
designed by replacing phosphate with the phosphonodifluoromethyl group.29 The negatively 
charged phosphonate oxygens were blocked with carboxyesterase-labile pivaloyloxymethyl 
(POM) groups as a means to permeate cells.30 Importantly, no biological evaluation was 
given, either in the patents or in peer-reviewed literature; therefore, it was not known 
whether this was a viable approach for the inhibition of STAT6 phosphorylation. Using our 
convergent methodology for the synthesis of phosphopeptide mimic prodrugs targeting SH2 
domains,31,32 we improved the synthesis of 17 and found that it indeed inhibited both IL-4 
and IL-13-stimulated phosphorylation of STAT6 in Beas-2B cells, an immortalized human 
bronchial epithelial cell line. Significant inhibition of pSTAT6 was observed at 
concentrations ≥1 µM.33
We embarked on new studies to test structural requirements of phosphate-containing 
analogues of prodrug 17 for affinity for the SH2 domain of STAT6. Interestingly, compound 
18a (IC50 = 0.04 µM) was approximately 100-fold more potent than the phosphopeptides 
based on the IL-4Rα docking site (1–16), which exhibited IC50 values of 2–15 µM. Given 
that 18a has the cinnamate group of 14 and the Tle-Pro group of 7, we conclude that placing 
the aryl groups closer to the proline in 18a than that of Phe in the peptides is responsible for 
the increase in affinity. For STAT3 inhibitors, we found that substitution of a methyl group 
on the β position of the phosphocinnamate pTyr surrogate enhanced affinity 2–3-fold (pCinn 
vs βMpCinn).31 In keeping with these results, substitution of βMpCinn for pCinn produced 
a 2-fold increase in affinity 19a vs 18a (Table 4). 7-Phosphoryl-indole 2-carboxylate (20) 
reduced affinity compared to 4-phosphoryloxycinnamate, also consistent with our 
observations of inhibitors of STAT3.28
The literature describing 17 emphasized C-terminal bis-aryl and aryl,benzyl amides and all 
of the compounds in the reported structure–affinity relationship studies possessed these 
structural features.23,24 To test the requirements of aryl groups, we prepared a series of 
analogues of 18a and 19a with varying C-terminal amide substitution (Table 5). In the 
cinnamate series, the diphenylamide (18b) has a 3-fold higher IC50 than 18a, indicating that 
the iodine contributed to affinity. Methylanilide 18c is 4-fold lower in affinity than 
diphenylamide 18b, suggesting that aromatics are indeed important at the C-terminus. 
Removal of the methyl group (18d) resulted in further loss in affinity. Not surprisingly, in 
the β-methylcinamate series, the same trend in affinity loss was observed with reduced aryl 
and methyl substitution on the C-terminal amide nitrogen (19a–d), although the affinities in 
this series were higher than those of 18a–d. No gain in affinity was achieved by adding one 
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or two methylene unit spacers to anilide 19d, see 19e and 19f. The cyclohexyl,methyl amide 
(19g) was 2-fold less avid than the phenyl,methyl amide, 19c. The dimethylamide, 19h, is 
significantly lower in affinity than the phenyl,-methyl amide. Affinity is improved with the 
larger diethylamide, 19i. These results show that while aryl groups are important at the C-
terminus, reasonable affinity can be achieved with alkyl amides.
Structural requirements of proline were probed (Table 6). For these experiments N-
methylanilides were employed at the C-terminus. Replacing proline with the acyclic, N-
methylated amino acid, sarcosine, 21, resulted in approximately 2-fold lower affinity than 
the proline-containing analogue, 19c, suggesting that relative to sarcosine, the 
conformational constraint of proline is important. Interestingly, alanine (22) was equipotent 
to proline, whereas N-methylation of the alanine (23) reduced affinity 4-fold. This suggests 
that the Tle–Pro peptide bond is likely in the trans conformation when bound to STAT6. 
Given that Xaa–Yaa peptide bonds sample significant cis conformations when Yaa is an 
imino acid, such as N-methyl alanine, the lower affinity of 23 relative to 22 may be due to 
the lower effective concentration of the trans conformer in the former.34
Contributions of the atoms of the C-terminal amide bond were studied by replacement with 
conformationally constrained vinyl analogues (Table 7). Substituting the CONH group of 
19d with a simple carbon–carbon double bond (24) reduced affinity over 10-fold. Extending 
the aliphatic chain by two methylene groups (25) increased affinity to 0.5 µM. Reduction of 
the vinyl group of 25 to an alkane (26) resulted in a slight decrease in affinity. Reduction of 
the carbonyl group of the methyl,phenyl amide of 19c resulted in a 4-fold loss in affinity 
(27). Thus, the carbonyl and nitrogen atoms of the C-terminal amide contribute to affinity 
for the SH2 domain of STAT6.
Computed Structure of 18a Bound to the SH2 Domain of STAT6
To date, our attempts to crystallize STAT6 either alone or in the presence of a 
phosphopeptide have not been successful. To elucidate potential interactions between 18a 
(the phosphate analogue of 17) and STAT6, we employed a molecular modeling strategy that 
combines an AutoDock-based incremental protocol of flexible protein–ligand docking 
(DINC) and molecular dynamics simulations.35,36 A homology model of STAT6, based on 
the template structure of STAT1 (PDB ID 1YVL, chain A), was obtained from ModBase.37 
Using DINC,35 18a was docked to the SH2 domain of STAT6. The complex was submitted 
to molecular dynamics simulation in explicit water. We obtained five clusters through k-
mean clustering (k = 5). The sizes of the clusters were 173, 115, 101, 59, and 52 frames. 
Throughout the simulation, RMSD variations of 18a were largely between 1 and 2.5 Å, 
indicating that the peptide mimetic in the complex was stable. In the computed models, the 
inhibitor interacts with the surface of the protein and there do not appear to be deep pockets 
(Figure 3A,B). Hydrogen bonds are illustrated in the interaction diagram of Figure 3C and 
the stereo rendering in Figure 3D. The phosphate participates in ionic interactions with 
Lys544 and Arg562 and hydrogen bonding interactions with the main chains of Asp565 and 
Ser566, which are analogous to phosphate interactions with STAT138,39 and STAT340 
observed in X-ray crystallographic structures and computational models of phosphopeptides 
bound to STAT3.28,36 These hydrogen bonds were very stable and were present in greater 
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than 90% of the trajectory frames throughout the molecular dynamics simulation. The 
exception was the interaction between O2 of the phosphate and one of the quanidino NH2 
groups of Arg562 (75% of trajectory frames). The hydrogen bond between the NH of Tle 
and the main chain C=O of Asn588 is typical of phosphopeptide interactions with SH2 
domains and was present in 83% of the trajectory frames. Also noted was a very stable 
hydrogen bond between the C=O of Tle and the main chain NH of Gln590 (100% of 
trajectory frames). Interactions between the C=O of the pY+1 residue and the NH of Glu638 
(analogous to Gln590) were also seen in computed models of phosphopeptides bound to 
STAT3.36,41 The aryl group of the cinnamate and the C-terminal iodophenyl group 
“sandwich” the side chain of Gln590, which extends away from the protein surface (Figures 
3A,B,D). Not surprisingly, there were several hydrophobic interactions with the SH2 domain 
of STAT6, which are depicted as orange surfaces in Figure 3A and which are summarized in 
the interaction diagram in Figure 3C. The tert-butyl group of Tle interacts with the side 
chain methylene groups of Glu587 and the side chain of His 575. The C-terminal benzene 
rings interact with a hydrophobic surface comprised of the side chains of Ile589, Phe592, 
Leu609, Leu612, Ile606, and the side chain CH2 groups of Arg605. This hydrophobic 
surface does not appear to be able to accommodate the side chain benzene ring of Phe at 
position pY+3 in the peptides, which is extended from the proline by the α and β carbons. 
Thus, the peptides exhibit lower affinity than the mimetics.
Inhibition of Stat6 Phosphorylation in Intact Cells with Prodrugs Derived from 
Phosphopeptide Mimetics
A set of analogues of 17 (Chart 1) was synthesized to systematically evaluate the effect of 
structural modifications on the ability to inhibit STAT6 phosphosphorylation in intact cells 
(Figure 4). Beas-2B immortalized human airway epithelial cells were incubated with 
prodrugs for 2 h and stimulated with IL-4 for 1 h. Levels of pSTAT6 and total STAT6 
proteins were evaluated by Western blotting of the cell lysates. The first series was a set of 
analogues of phosphates 18a–d. Starting with 17, possessing a phenyl, 4-iodophenyl amide, 
we removed the iodine (28) and then replaced one of the phenyl rings with a methyl group 
(29) then a hydrogen (30). As depicted in Figure 4A, removing the iodine from 1 resulted in 
a dramatic increase in potency (28). Significant inhibition was observed at 100 nM, and 
complete inhibition occurred at 500 nM. Substitution of one of the phenyl groups with a 
methyl group (29) produced a further increase in potency with significant inhibition at 50 
nM and nearly complete inhibition at 100 nM. Replacing the methyl group with a hydrogen 
(30) resulted in approximately 25-fold less potency. Cellular viability (MTS assay, 72 h 
exposure, Figure 4C) did not parallel potency for STAT6 inhibition. The trend NPh,PhI < 
NPh2 < NMePh < NHPh indicates that smaller amides result in greater cytotoxicity. At 
concentrations ≤1 µM, diphenyl amide 28 and methylanilide 29 did not affect viability 
although pSTAT6 was completely inhibited. Thus, for these compounds, the reason for the 
observed cytotoxicity is not STAT6 phosphorylation inhibition. In contrast, for 30, the 
fraction of viable cells paralleled pSTAT6 inhibition. These results suggest that the C-
terminal anilide is engaged in an as yet undefined off-target interaction that produces a 
cytotoxic effect.
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A second set of prodrugs was prepared to test the effect of β-methyl substitution on the 
cinnamate on cellular activity, as this substitution produced a small but significant increase 
in affinity of the phosphate analogues. Figure 4B shows that 31, the analogue of 29, retains 
potency and the β-methyl group has no noticeable effect on inhibition of pSTAT6. In 32, a 
cyclohexyl, methyl amide group replaced the phenyl,methyl amide of 31. As can be seen, 
this substitution also resulted in high potency. Cell viabilities of 31 and 32 were nearly 
identical to that of 29. Thus, the β-methyl group has no effect on cytotoxicity in this cell 
line.
Interestingly, cellular potency did not parallel affinity for STAT6 of the corresponding 
phosphates, 18a–d and 19c and 19g. Whereas affinity of the phosphate series decreased with 
decreasing aromatic character or decreasing methyl substitution, this was not the defining 
feature for the prodrug potency. Similar observations were made in the case of our prodrugs 
targeted to the SH2 domain of STAT3. For example, changing the C-terminal CONHBn to a 
simple methyl group in one series reduced affinity by a factor of 2 but increased cellular 
potency of the prodrug by 50-fold.31 In another series, substitution on the ring of a proline 
had no effect on affinity but increased cellular potencies from 20 to 100×.42 Thus, for this 
class of phosphonate prodrugs, biochemical affinity of the ligand for the target SH2 domain 
is not linearly predictive of cellular activity.
Other Cell Lines and Other SH2 Domains
The panel of prodrugs was tested for pSTAT6 inhibition in the triple negative breast cancer 
cell line, MDA-MB-468. After serum starvation, cells were treated with prodrugs followed 
by IL-4 stimulation which resulted in pSTAT6 inhibition. Overall, the pattern of inhibition 
paralleled that of the Beas-2B epithelial airway cells (Supporting Information Figure S1). 
Treatment of serum starved MDA-MB-468 cells with epidermal growth factor (EGF) 
activates the PI3K pathway leading to AKT phosphorylation,43 a process that is initiated by 
binding of the SH2 domain of p85, the regulatory subunit of PI3K, to pTyr residues on the 
EGF receptor.44 There was no clear trend for inhibition of pAkt as a function of structure. 
Whereas most compounds had no effect, 29 and 31 exhibited mild inhibition at the relatively 
high concentration of 5 µM. The exception was anilide 30, which potently inhibited pAkt at 
concentrations as low as 100 nM. MTS assays showed that for the panel of prodrugs, IC50 
values for this cell line ranged from 5 to 10 µM. It is unclear if the decrease in pAkt is due to 
cross reactivity with the SH2 domains of p85 or due to other nonrelated offtarget effects that 
might affect this pathway.
The panel of prodrugs was assayed for the ability to inhibit the phosphorylation of STAT1, 
STAT3, STAT5, and STAT6 in primary mouse CD4+ T lymphocytes (Supporting 
Information Figure S2). Similarly to Beas-2B cells, inhibition of IL-4 stimulated pSTAT6 
with 17 was relatively weak and the others stronger. We further found robust inhibition of 
IL-2 mediated STAT5 phosphorylation after treatment with 29, 28, 31, and 32. This is not 
surprising given the high homology in the SH2 domains of these two proteins. The 
hydrophobic surface mentioned above for STAT6 (Ile589, Phe592, Are605, Ile606, Leu609, 
and Leu612) is highly homologous in STAT5 (L643, Phe646, Are661, Leu662, Leu665, and 
Leu668). The side chain CH2 groups of Lys644 in STAT5 can also contribute to the 
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hydrophobic binding site in an analogous manner to that of Gln590 in STAT6. Interestingly, 
anilide 30 showed selectivity for STAT6 as it was not an inhibitor of pSTAT5. None of the 
prodrugs affected the phosphorylation status of STAT1 or STAT3.
Inhibition of the Expression of CCL26 (Eotaxin-3)
Starting prodrug 17 and analogue 31 were tested for their ability to inhibit the expression of 
the downstream gene, CCL26 (eotaxin-3), a chemokine involved in the recruitment of 
eosinophils to sites of inflammation.45,46 Beas-2B cells were treated with the inhibitors, and 
after 24 h of exposure to IL-13, expression of CCL26 mRNA was assessed by quantitative 
PCR. As can be seen in Figure 5, addition of IL-13 led to robust expression of CCL26 
mRNA (DMSO+). The expression of CCL26 mRNA was inhibited in a dose-dependent 
manner by both prodrugs. In both cases, >50% inhibition was achieved at 100 nM. The 
greater potency of 31 reflects its greater ability to inhibit STAT6 phosphorylation than 17. 
Thus, steric block of the STAT6 SH2 domain with these prodrugs not only inhibits activation 
(phosphorylation of Tyr641), it inhibits subsequent transcriptional activity.
Chemistry
Phosphopeptide Synthesis—Phosphopeptides in Tables 1–3 were synthesized by 
manual solid phase techniques using the Fmoc protection scheme. C-termini were prepared 
as amides by the employment of Rink amide resin. N-Termini were capped with acetyl 
groups unless otherwise noted. Phosphotyrosine was introduced as the phosphoro-bis-
dimethylamide.47–49 For the 5-phosphoryloxyindole (15) and 5-
phosphoryloxybenzofurnan-2-carboxylates (16), the corresponding 5-hydroxy-2-
carboxylates were coupled to resin-bound peptides and were phosphorylated using global 
phosphorylation with N,N-diisopropyl-di-tert-butylphosphoramidite in the presence of 1H-
tetrazole. Peptides terminating in 4-phosphoryloxycinnamide and 4-phosphoryloxy-β-
methylcinnamide were capped with the corresponding phosphorylated cinnamic acid-
pentachlorophenyl esters as described previously.28 Peptides were cleaved from the resin 
using TFA:TIS:H2O.50 Peptides containing phosphoro-bis-dimethylamides were left 
overnight to deamidate the phosphate group.47–49 All phosphopeptides were purified by 
reverse phase HPLC and were the correct molecular weight as measured by electrospray 
mass spectrometry.
Synthesis of Phosphate Analogues of 17—We used convergent synthesis 
methodology to prepare phosphates for analysis of affinity for STAT6 protein in which 
modified dipeptides were synthesized and coupled to preformed constrained 
phosphotyrosine surrogates. For inhibitors 18–20 possessing constrained cinnamate and 
indole-based pTyr mimics (Table 4), diphenyl and phenyl,4-iodophenyl amines were not 
amenable to simple coupling to Boc-proline (33). In these cases, the first aryl group was 
installed as the anilide or 4-iodophenylamide of Boc-Pro-OH using water-soluble EDC as 
the coupling agent (34a,b) (Scheme 1). The second phenyl group was added by treatment 
with triphenylbismuth in the presence of cupric acetate and triethyl amine (35a,b).51,52 The 
Boc group was removed with TFA, and the resulting amine was coupled to Boc-tertiary-
leucine with HBTU (36a,b). Again the Boc group was removed to give dipeptide amine salts 
37a and 37b. Intermediate 37a was capped with pentachlorophenyl 4-
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phosphoryloxycinnamate (38a)28 and pentachlorophenyl β-methyl-4-
phosphoryloxycinnamate (38b)31 to give inhibitors 18a and 19a (Table 4), respectively. 
Amine 37b was acylated with 38a and 38b to give 18b and 19b, respectively (Table 5). The 
alternative pTyr surrogate, 5-phosphoryloxyindole-2-carboxylate, was introduced by 
coupling 37a with 5-di-tertiary-butoxyphosphoryl-indoline-2-carboxylic acid (Scheme 2) 
(39) in the presence of HBTU and DIPEA. Treatment with TFA for an hour and purification 
by HPLC gave 20 (Table 4).
As shown in Scheme 2, 5-di-tertiary-butoxyphosphorylindoline-2-carboxylic acid (39) was 
prepared by protection of the carboxyl group of 5-hydroxyindole-2-carboxylate (40) as a 
tert-butyl dimethylsilyl (TBDMS) ester (41), followed by phosphitylation of the hydroxyl 
group with N,N-diethyl di-tert-butyl phosphoramidite and subsequent oxidation to the 
phosphate ester with tert-butyl hydrogen peroxide (42). Aqueous hydrolysis of the TBDMS 
ester gave the free carboxylate, 39 ready for capping 37a (Scheme 1).
Inhibitors in which the C-terminal amide was explored (18c,d, 19c–i, Table 5) were prepared 
by initial routine coupling of amines to Boc-proline using EDC (43c–i, Scheme 3). The Boc 
group was removed with TFA and Boc-tertiary-leucine was coupled with HBTU (44c–i). 
Again, the Boc group was removed and the dipeptides were capped with 38a or 38b to give 
inhibitors 18c–d and 19c–i.
Inhibitors 21–23 (Table 6), in which proline was replaced with nonconstrained sarcosine, 
alanine, and N-methylalanine, respectively, were prepared by simple coupling of N-
methylaniline to the corresponding Boc-amino acid and elaborating as in Scheme 3.
Inhibitors 24–27 (Table 7) were synthesized to establish the importance of the C-terminal 
amide bond. As shown in Scheme 4, (S)-2-styryl-N-Boc-pyrrolidine (46) and (S)-2-(3-
phenyl-propenyl)-N-Boc-pyrrolidine (48) were synthesized through a Wittig olefination of 
Boc-prolinal (45) and the corresponding triphenylphosphonium bromide derivative. Fully 
reduced (S)-2-(4-phenylbutyl)-N-Boc-pyrrolidine (50) was obtained by hydrogenation of 48 
in the presence of 10%Pd-C. An analogue with a reduced amide bond was prepared by 
consecutive reductive-amination of Boc-prolinal with aniline (52) and then with 
formaldehyde (40% solution) (53). Intermediates 46, 48, 50, and 53 were elaborated to 
dipeptide amines 47, 49, 51, and 54 by TFA-mediated acidolysis of the Boc protecting 
group, HBTU-mediated coupling with Boc-Tle-OH, and then Boc cleavage with TFA as in 
Scheme 3. Treatment of the amine salts with 39b gave inhibitors 24–27.
Cell permeable prodrugs (Chart 1) were synthesized (Scheme 5) by coupling dipeptide 
amines to pentachlorophenyl active esters of bis-POM protected 
phosphonodifloromethylcinnamates 55a or b that were synthesized as described 
previously.31,32 Couplings were carried out in NMP in the presence of N-methylmorpholine 
with DMAP catalysis. Products were purified by reverse phase HPLC with gradients of 
MeCN in H2O with no additives in the mobile phase.
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CONCLUSIONS
The sequence surrounding Tyr631, the docking site of IL-4Rα, binds weakly to STAT6. This 
contrasts with STAT3 where a peptide derived from the docking site on gp130 (Tyr904) had 
low nM affinities.53,54 In the modified dipeptides reported by McKinney et al.,23,24 the aryl 
groups at pY+3 were closer to the main chain than the phenyl group of phenylalanine in the 
phosphopeptide series. Whereas C-terminal aryl amides produced the highest affinity, low 
nM binding constants could also be obtained with N-methyl anilides and dialkyl amides. The 
smaller hydrophobic groups of the latter likely do not penetrate as deeply into the proposed 
hydrophobic pocket as do benzene rings. Cellular potency of the bis-POM prodrugs was 
dependent on the substituents of the C-terminal amide but did not parallel affinity for STAT6 
by the corresponding phosphates. Cellular activity of a peptidomimetic or any other drug is a 
function of many factors that may include (1) the intrinsic affinity of the drug for its target 
(e.g., enzyme, transcription factor, miRNA), (2) effectiveness of cell penetration, (3) efflux 
from the cell, (4) metabolic stability, (5) partitioning into membranes versus the cytosol, and 
other possible interactions. It is not clear which of these factors contributes to the deviation 
in cellular potency of the prodrugs from affinity for STAT6 of the corresponding phosphates. 
Inhibition of cell viability was inversely proportional to the size of the C-terminal amide 
with the smaller methylanilide and anilide analogues being most inhibitory. These apparent 
off-target effects can potentially induce more than one type of biological response in vivo, 
and it will be necessary to carefully monitor toxicity in animal studies. The prodrugs were 
quite potent in inhibiting expression of CCL26, suggesting that this class of compounds will 
have utility in modulating immune responses. In the case of asthma, cytotoxicity is 
detrimental, so care will have to be exercised to achieve the therapeutic window. The 
inhibitors were selective for STAT6 over STAT1 and STAT3. The basis of the selectivity can 
be explained as follows. At the base of the hydrophobic pocket that accommodates the C-
terminal aromatic groups in STAT6 is Phe592. In the sequences of STAT1, STAT2, STAT3, 
and STAT4, the corresponding residue is a tyrosine. In the crystal structure of a 
phosphopeptide bound to STAT1,39 and in models calculated for phosphopeptide–STAT3 
complexes,28,36,41 the side chain hydroxide of this tyrosine contacts a main chain peptide 
bond in a hydrogen bond which appears to be part of the recognition determinant for these 
SH2 domains. On the basis of these models, this hydroxyl group, and associated waters of 
hydration, in STAT1 and STAT3 would repel the C-terminal amide aromatic groups of the 
inhibitors, thus leading to selectivity for STAT6 (and STAT5). The observed cross reactivity 
to STAT5 in asthma is not likely to be a problem in clinical settings. As STAT5 was reported 
to be required for the asthma phenotype in a STAT6-independent manner,55 cross reactivity 
to STAT5 may actually contribute to in vivo efficacy. Evaluation of prodrugs in a fungal-
induced murine model of asthma is in progress and will be reported under separate cover.
METHODS
Na-protected amino acids were purchased from, ChemImpex or NovaBiochem. HOBt was 
from ChemImpex. For the synthesis of phosphopeptides, Rink resin (Advanced Chemtech, 
Inc.) with a loading of 0.6 mmol/g was employed. Anhydrous DMF for amino acid solutions 
and aniline derivatives were from Aldrich. Other solvents were reagent grade and were used 
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without further purification. NMR spectra were obtained on either a Bruker DPX 300 MHz 
spectrometer or a Bruker DRX 500 MHz spectrometer.
General Procedure for the Synthesis of Phosphopeptides
Solid phase syntheses were carried out manually using commercially available Rink resin. 
Resin, 0.2 g, was placed in a manual reactor and swollen and washed with 5 × 10 mL of 
DMF/CH2Cl2. Fmoc groups were removed with 3 × 6 mL of 20% piperidine/DMF for 5 min 
each. For coupling, 3-fold excesses of Fmoc-amino acids, DIC, and HOBt were used in 8–10 
mL of DMF/CH2Cl2 and were allowed to proceed until resin samples tested negative with 
ninhydrin tests. After coupling and deprotection steps, resins were washed with 5 × 10 mL 
of DMF/CH2Cl2. On completion of the peptide chain, resins were washed with CH2Cl2 (3 × 
10 mL) and were treated with TFA:TIS:H2O (95:2.5:2.5) (3 × 5 mL) for 15 min each. The 
combined filtrates volumes were reduced in vacuo. Peptides were precipitated in Et2O and 
collected by centrifugation. After drying, peptides were purified by reverse phase HPLC on 
a Varian Dynamax HPLC using a Phenomenex Luna C18 (2) 10 µM, 2.1 cm × 25 cm 
column. Gradients of 0.1% TFA–MeCN in 0.1% TFA–H2O with a flow rate of 20 mL/min 
were employed. For prodrugs, no TFA was used in the mobile phase. Peptides were tested 
for purity by reverse phase HPLC on a Waters Alliance HPLC using a Phenomenex Luna 
C18 (2) 5 µM 2.1 mm × 250 mm column at a flow rate of 0.4 mL/min. A gradient of 0–40% 
MeCN/30 min was used for phosphopeptides and peptide intermediates. For prodrugs the 
gradient was 10–80% MeCN/30 min. Phosphopeptides and prodrug intermediates were 
dried in vacuo over P2O5 at 37° for 24 h prior to use.53 All compounds were >95% pure 
(HPLC) before evaluation. Purities, yields, and mass spectral characteristics of 
phosphopeptides and prodrugs are provided in the Supporting Information.
Synthesis of 4-(Di-tert-butoxyphosphoryloxy)-Indole-2-carboxylic Acid, 39—To 
a suspension of 5-hydroxyindole-2-carboxylic acid (1.0 g, 5.64 mmol) and tert-
butyldimethylsilyl chloride (0.85g, 5.64 mmol) in 10 mL of dry THF, N-methylmorpholine 
(0.62 mL, 5.64 mmol) was added at room temperature. After 15 min, 1H-tetrazole (1.6 g, 
22.56 mmol) was added in one portion followed by the addition of di-tert-butyl N,N-
diethylphosphoramidite (3.9 g, 11.3 mmol) in 15 mL of dry THF. After stirring for 2 h, 70% 
aq tert-butylhydroperoxide (3.0 mL, 16.9 mmol) was added at 0 °C and the mixture was 
stirred for 2 h more. The reaction was quenched with slow addition of an aqueous solution 
of 10% Na2S2O5 and stirred for 1.0 h. It was then diluted with ethyl acetate (30 mL) and 
extracted with an additional amount of ethyl acetate (2 × 20 mL). The combined organic 
parts were washed with water, followed by brine and dried (MgSO4). Solvent was removed, 
and the crude product was triturated with hexane–ether. The product was collected by 
filtration and dried to give 1.5 g (71%) of a white solid, which was used without further 
purification. 1H NMR (DMSO-d6, 300 MHz) δ 1.26 (s, 18H), 6.88–6.94 (m, 2H), 7.21–7.26 
(m, 2H), 11.62 (s, 1H). 13C NMR (DMSO-d6, 75 MHz) δ 29.9, 83.1, 83.2, 107.8, 112.0, 
113.6, 118.5, 127.3, 130.1, 134.8, 145.2, 145.3, 163.1. MS (ESI) m/z: (M + 1)+ calcd, 370.3; 
found, 370.4.
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General Procedure for Boc-prolinamide Formation
A solution of Boc-proline (1.0 g, 4.64 mmol), the appropriate amine (1.0 equiv), and EDC 
(1.2 equiv) in 60 mL of dry dichloromethane was stirred for overnight. It was then 
transferred to a separatory funnel with an additional 20 mL of CH2Cl2 and washed with 5% 
HCl (2 × 30 mL) followed by 10% NaHCO3 (2 × 30 mL) and brine (1 × 20 mL). The 
organic layer was dried (MgSO4) and concentrated under reduced pressure. The residue was 
used as such for the next step or purified by flash chromatography with gradients of EtOAc 
in hexanes.
Boc-Pro-NHPhI, 34a—See ref 33.
Boc-Pro-NHPh, 34b—Yield 1.2 g, 90%, starting from 4.64 mmol of Boc-proline. 1H 
NMR (300 MHz, CDCl3) δ 1.5 (s, 9H), 1.91–1.95 (m, 3H), 2.52 (m, 1H) 3.44 (m, 2H), 4.44 
(m, 1H), 7.1 (m, 1H), 7.3 (t, J = 7.6 Hz, 2H), 7.5 (d, J = 8.0 Hz, 2H), 9.5 (brs, 1H). MS (ESI) 
m/z: (M + 23)+ calcd, 313.2; found, 313.3
Boc-Pro-N(Me)Ph, 43c—Yield 1.1 g, 78%, starting from 4.64 mmol of Boc-proline. 1H 
NMR (300 MHz, CDCl3) δ 1.45 (s, 9H), 1.48 (isomer, s, 9H), 1.65–2.0 (m, 4H), 3.28 (s, 
3H), 3.3–3.47 (m, 1H), 3.5–3.6 (m, 1H), 4.14 (m, 1H), 4.3 (isomer, m, 1H), 7.2–7.47 (m, 
5H). MS (ESI) m/z: (M + 23)+ calcd, 327.2; found, 327.3.
Boc-Pro-NHCH2Ph, 43e—Yield 1.3 g, 92%, starting from 4.64 mmol of Boc-proline. 1H 
NMR (300 MHz, CDCl3) δ 1.4 (s, 9H), 1.82–1.98 (m, 2H), 2.1–2.43 (m, 2H), 3.4 (m, 2H), 
4.2–4.65 (m, 3H), 6.4 (brs, 1H), 7.24–7.34 (m, 5H). MS (ESI) m/z: (M + 23)+ calcd, 327.2; 
found, 327.3.
Boc-Pro-NHCH2CH2Ph, 43f—Yield 1.2 g, 85%, starting from 4.64 mmol of Boc-
proline. 1H NMR (300 MHz, CDCl3) δ 1.42 (s, 9H), 1.74–1.9 (m, 2H), 1.95–2.4 (m, 2H), 
2.7–2.9 (m, 2H), 3.27–3.4 (m, 2H), 3.4–3.6 (m, 2H), 4.22 (m, 1H), 7.2–7.33 (m, 6H). MS 
(ESI) m/z: (M + 23)+ calcd, 341.2; found, 341.3.
Boc-Pro-N(Me)C6H11, 43g—Yield 1.1 g, 76%, starting from 4.64 mmol of Boc-
proline. 1H NMR (300 MHz, CDCl3) δ 1.05–1.2 (m, 1H), 1.25–1.48 (m, 14H), 1.5–1.73 (m, 
4H), 1.74–2.25 (m, 6H), 2.8 (s, 1.5H), 2.9 (s, 1H), 2.92 (s, 1H), 3.4–3.7 (m, 2H), 4.4 (m, 
0.5H), 4.5 (m, 0.5H), 4.65 (m, 0.5H). MS (ESI) m/z: (M + 23)+ calcd, 333.2; found, 333.3
Boc-Pro-NMe2, 43h—Yield 1.0 g, 79%, starting from 4.64 mmol of Boc-proline. 1H 
NMR (300 MHz, CDCl3) δ 1.4 (s, 9H), 1.46 (isomer, s, 9H), 1.78–1.92 (m, 4H), 1.96–2.23 
(isomer, m, 4H), 2.96 (s, 3H), 2.97 (isomer, s, 3H), 3.06 (s, 3H), 3.1 (isomer, s, 3H), 3.4–3.5 
(m, 2H), 3.53–3.66 (isomer, m, 2H). 4.55 (m, 1H), 4.67 (m, 1H). MS (ESI) m/z: (M + 23)+ 
calcd, 265.2; found, 265.3
Boc-Pro-NEt2, 43i—Yield 1.1 g, 87%, starting from 4.64 mmol of Boc-proline. 1H NMR 
(300 MHz, CDCl3) δ 1.08–1.18 (m, 6H), 1.2–1.28 (isomer, m, 6H), 1.4 (s, 9H), 1.45 (s, 
9H), 1.76–1.92 (m, 4H), 1.97–2.23 (isomer, m, 4H), 3.2–3.7 (m, 12H, including isomer), 
4.45 (m, 1H), 4.6 (m, 1H). MS (ESI) m/z: (M + 23)+ calcd, 293.2; found, 293.3
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General Procedure for Arylation of Amides..51,52
To a stirred solution of amide 34a or b (5.0 mmol) in dry CH2Cl2 (50 mL) was added 
triphenylbismuth (2.0 equiv), Cu(OAc)2 (2.0 equiv), and dry triethylamine (3.0 equiv). After 
completion of the reaction (as monitored by HPLC), the solvent was evaporated and the 
residue was diluted with ether (150 mL) and filtered through Celite. The filtrate was then 
washed with 5% HCl (2 × 30 mL) followed by brine and was dried over MgSO4. 
Concentration under reduced pressure followed by purification by silica gel chromatography 
using 10% ethyl acetate–hexane mixture afforded the title compounds.
Boc-Pro-N(Ph)PhI, 35a—See ref 33.
Boc-Pro-NPh2, 35b—Yield 0.9 g, 71%, starting from 3.44 mmol of 35b. 1H NMR (600 
MHz, CDCl3) δ 1.46 (s, 9H), 1.52 (s, 9H, isomer), 1.72–1.8 (m, 2H), 1.87–1.94 (m, 1H), 
1.96–2.1 (m, 5H), 3.36–3.4 (m, 1H), 3.46–3.5 (m, 1H), 3.55–3.64 (m, 2H), 4.3 (m, 1H), 4.44 
(m, 1H), 7.1–7.5 (m, 20H, including isomer). MS (ESI) m/z: (M + 23)+ calcd, 389.2; found, 
389.3
General Procedure for Dipeptide Formation
A solution of the appropriate Boc-prolinamide (2.0 g) in 10 mL of 95%TFA/CH2Cl2 was 
stirred for 1 h. The solution was concentrated under vacuum. Residual TFA was stripped off 
with by the addition and evaporation of CCl4 (2 × 10 mL). The residue was treated with 
Boc-Tle-OH (1.2 equiv), HBTU (1.2 equiv), and DIEA (2.5 equiv) in 50 mL of dry CH2Cl2 
for overnight. The organic layer was then diluted with an additional 50 mL of CH2Cl2 and 
washed with 5% HCl (3 × 30 mL) followed by 10% NaHCO3 (2 × 30 mL) and brine. After 
drying (MgSO4) and concentration under vacuum, crude products were sufficiently pure and 
were used as such for the next step.
Boc-Tle-Pro-N(Ph)PhI, 36a—See ref 33.
Boc-Tle-Pro-NPh2, 36b—Yield 0.7 g, 77%, starting from 1.9 mmol of H-Pro-NPh2. 1H 
NMR (600 MHz, CDCl3) δ 1.06 (s, 9H), 1.40 (s, 9H), 1.83 (m, 1H), 1.97–2.06 (m, 3H), 
3.73 (m, 1H), 3.83 (m, 1H), 4.30 (d, J = 9.6 Hz, 1H), 4.55 (m, 1H), 5.38 (d, J = 9.6 Hz, 1H), 
7.15–7.52 (m, 10H). MS (ESI) m/z: (M + 23)+ calcd, 502.3; found, 502.5
Boc-Tle-Pro-N(Me)Ph, 44c—Yield 0.69 g, 68%, starting from 2.44 mmol of H-Pro-
N(Me)Ph. 1H NMR (600 MHz, CDCl3) δ 1.00 (s, 9H), 1.32 (s, 9H), 1.64–1.72 (m, 1H), 
1.78 (m, 2H), 1.96 (m, 1H), 3.2 (s, 3H), 3.62 (m, 1H), 3.72 (m, 1H), 4.22 (d, J = 9.6 Hz, 1H), 
4.34 (t, J = 7.4 Hz, 1H), 5.28 (d, J = 9.6 Hz, 1H), 7.26–7.38 (m, 5H). MS (ESI) m/z: (M 
+ 23)+ calcd, 440.3; found, 440.5
Boc-Tle-Pro-NHPh, 44d—Yield 0.83 g, 79%, starting from 2.63 mmol of H-Pro-
NHPh. 1H NMR (600 MHz, CDCl3) δ1.00 (s, 9H), 1.44 (s, 9H), 1.9 (m, 1H), 2.03 (m, 1H), 
2.16 (m, 1H), 2.55 (m, 1H), 3.66 (m, 1H), 3.82 (m, 1H), 4.35 (d, J = 9.7 Hz, 1H), 4.83 (m, 
1H), 5.26 (d, J = 9.6 Hz, 1H), 7.05 (m, 1H), 7.27 (m, 2H), 7.47 (m, 2H), 9.37 (brs, 1H). MS 
(ESI) m/z: (M + 23)+ calcd, 426.3; found, 426.4
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Boc-Tle-Pro-NHCH2Ph, 44e—Yield 0.72 g, 71%, starting from 2.45 mmol of H-Pro-
NHCH2Ph. 1H NMR (600 MHz, CDCl3) δ 0.88 (s, 9H), 1.42 (s, 9H), 1.85–1.9 (m, 1H), 
1.92–2.0 (m, 1H), 2.14 (m, 1H), 2.41–2.45 (m, 1H), 3.61 (m, 1H), 3.75 (m, 1H), 4.26 (d, J = 
9.6 Hz, 1H), 4.32 (dd, J = 5.4 and 15.0 Hz, 1H), 4.46 (dd, J = 6.6 and 15.0 Hz, 1H), 4.63 
(dd, J = 2.4 and 7.8 Hz, 1H), 5.2 (d, J = 9.6 Hz, 1H), 7.23–7.30 (m, 5H). MS (ESI) m/z: (M 
+ 23)+ calcd, 440.3; found, 440.4
Boc-Tle-Pro-NHCH2CH2Ph, 44f—Yield 0.53 g, 66%, starting from 1.83 mmol of H-Pro-
NHCH2CH2Ph. 1H NMR (600 MHz, CDCl3) δ 0.96 (s, 9H), 1.42 (s, 9H), 1.88–1.96 (m, 
2H), 2.06–2.09 (m, 1H), 2.28 (m, 1H), 2.74–2.81 (m, 2H), 3.47 (m, 2H), 3.61 (m, 1H), 3.77 
(m, 1H), 4.3 (d, J = 9.6 Hz, 1H), 4.53 (m, 1H), 5.28 (d, J = 9.6 Hz, 1H), 6.9 (m, 1H), 7.16–
7.21 (m, 3H), 7.27–7.3 (m, 2H). MS (ESI) m/z: (M + 23)+ calcd, 454.3; found, 454.5
Boc-Tle-Pro-N(Me)C6H11, 44g—Yield 0.62 g, 61%, starting from 2.38 mmol of H-Pro-
N(Me)C6H11. 1H NMR (600 MHz, CDCl3) δ 1.04 (s, 6H), 1.05 (s, 3H), 1.3–1.4 (m, 4H), 
1.4–1.44 (m, 11H), 1.53–1.61 (m, 1H), 1.62–1.7 (m, 2H), 1.74–1.8 (m, 1H), 1.81–1.9 (m, 
2H), 1.9–2.00 (m, 1H), 2.06–2.24 (m, 2H), 2.8 (s, 1H), 2.95 (s, 2H), 3.6 (m, 0.5H), 3.73 (m, 
1H), 3.86 (m, 1H), 4.3–4.4 (m, 1.5H), 4.83 (m, 0.5H), 4.9 (m, 0.5H), 5.35 (m, 1H). MS 
(ESI) m/z: (M + 23)+ calcd, 389.2; found, 389.3
Boc-Tle-Pro-NMe2, 44h—Yield 1.1 g, 60%, starting from 4.92 mmol of H-Pro-NMe2. 1H 
NMR (600 MHz, CDCl3) δ 1.04 (s, 9H), 1.42 (s, 9H), 1.86 (m, 1H), 1.95 (m, 1H), 2.1 (m, 
1H), 2.18 (m, 1H), 2.94 (s, 3H), 3.11 (s, 3H), 3.74 (m, 1H), 3.86 (m, 1H), 4.33 (d, J = 9.6 
Hz, 1H), 4.87 (m, 1H), 5.29 (d, J = 9.6 Hz, 1H). MS (ESI) m/z: (M + 23)+ calcd, 378.3; 
found, 378.4
Boc-Tle-Pro-NEt2, 44i—Yield 1.4 g, 64%, starting from 5.9 mmol of H-Pro-NEt2. 1H 
NMR (600 MHz, CDCl3) δ 1.03 (s, 9H), 1.1 (t, J = 7.2 Hz, 3H), 1.27 (t, J = 7.2 Hz, 3H), 
1.42 (s, 9H), 1.86–1.96 (m, 2H), 2.12–2.18 (m, 2H), 3.28–3.42 (m, 3H), 3.53 (m, 1H), 3.73 
(m, 1H), 3.87 (m, 1H), 4.32 (d, J = 10.2 Hz, 1H), 4.76 (m, 1H), 5.34 (d, J = 9.6 Hz, 1H). MS 
(ESI) m/z: (M + 23)+ calcd, 406.3; found, 406. 5
Synthesis of (S)-2-Styryl-N-Boc-pyrrolidine, 46.56—n-BuLi (1.0 mL, 2.5 mmol) was 
added dropwise via syringe over 10 min to a solution of benzyl-triphenylphosphonium 
bromide (1.0 g, 2.3 mmol) in 20 mL of dry THF under argon at −78 °C. The mixture was 
stirred for 1 h, then Boc-L-prolinal (0.46g, 2.3 mmol) in 20 mL of THF was added dropwise. 
The reaction was allowed to stir for 24 h at room temperature. The reaction mixture then 
quenched with 30 mL of saturated NH4Cl, diluted with ethyl acetate, washed with brine (2 × 
25 mL), dried over sodium sulfate, and concentrated in vacuo. Silica gel chromatography 
(5:1 hexanes/EtOAc) yielded 0.480 g (76%). 1H NMR (CDCl3, 300 MHz) δ 1.42 (s, 9H), 
1.8–2.2 (m, 4H), 3.45 (brs, 1H), 4.3–4.8 (m, 1H), 5.58–6.15 (m, 1H), 6.35–6.45 (m, 1H), 
7.2–7.4 (m, 5H).
Synthesis of (S)-2-(4-Phenyl-but-1-enyl)-N-Boc-pyrrolidine, 48—The same 
procedure as described for the synthesis of 46 was followed starting with 1.0 g of (3-
phenylpropyl)-triphenylphosphonium bromide (2.2 mmol) and 0.483 g of Boc-prolinal (2.2 
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mol). Yield: 0.452 g (1.5 mmol, 68%). 1H NMR (CDCl3, 300 MHz) δ 1.43 (s, 9H), 1.68– 
1.92 (m, 4H), 2.37–2.52 (m, 2H), 2.56–2.81 (m, 2H), 3.3–3.42 (m, 2H), 4.45 (brs, 1H), 
5.27–5.45 (m, 2H), 7.14–7.31 (m, 5H).
(S)-4-Phenbutyl-N-Boc-pyrrolidine, 50—A 50 mL round-bottom flask fitted with a 
three-way tap and balloon was charged with 400 mg of 10% Pd-C. Alkene 49 (405 mg) in 5 
mL of EtOH was added via syringe and stirred for 2 h. Hydrogen gas was added as the 
balloon deflated. Upon complete reaction (TLC), the catalyst was removed by filtration. The 
product was concentrated in vacuo to yield a colorless oil, yield 376 mg (93%). 1H NMR 
(CDCl3, 300 MHz) δ 7.15–7.31 (m, 5H), 3.70–3.76 (br m, 1H), 3.26–3.41 (m, 2H), 2.58–
2.64 (m, 2H), 1.59–1.93 (m, 7H), 1.49 (s, 9H), 1.30–1.35 (m, 3H).
Synthesis of N-Boc (S)-2-((Methyl(phenyl)amino)methyl)-pyrrolidine, 53—To a 
stirred solution of 45 (1.00 g, 5.02 mmol) and aniline (0.78 g, 6.02 mmol) in MeOH:acetic 
acid (9:1) (10 mL) was added NaCNBH3 (0.63 g, 10.04 mmol) at room temperature. The 
mixture was stirred for 1 h, evaporated to dryness, and the residue extracted with AcOEt (2 
× 30 mL). The organic phase was washed with 5% NaHCO3, brine, dried (MgSO4), and 
evaporated. The product 52 (1.0 g, 3.2 mmol) was then dissolved in 10 mL of MeCN:acetic 
acid (9:1), and 37% formalin (10 mL) and sodium cyanoborohydride (0.6 g, 9.6 mmol) were 
added. The mixture was stirred for 4 h at room temperature. The solution was evaporated in 
vacuo, and the residue was dissolved in AcOEt (50 mL) and was washed with 1N KOH 
followed by brine. The organic phase was dried (MgSO4) and evaporated, and the crude 
product was purified by silica gel chromatography using 30% EtOAc–hexane mixture 
yielding 0.640 g (2.2 mmol) of 53 (61%). 1H NMR (CDCl3, 300 MHz) δ1.52 (s, 9H), 1.8–
1.95 (m, 4H), 2.98 (s, 3H), 3.0–3.21 (m, 1H), 3.28–3.48 (m, 2H), 3.56–3.72 (m, 1H), 4.15 
(m, 1H), 6.68 (m, 1H), 6.74–6.84 (m, 2H), 7.18–7.26 (m, 2H). MS (ESI) m/z: (M + H)+ 
calcd, 291.2; found, 291.3.
General Procedure for Phosphopeptide/Phosphopeptidomimetic Formation
Boc-protected dipeptide (0.5 g) was treated with 5.0 mL of 95% TFA–CH2Cl2 for 1 h. After 
concentration under vacuum, the residue was diluted with 10 mL of water, neutralized with 
conc NH4OH, and lyophilized to obtain an off-white foam. The amine was then treated with 
the active ester (38a or 38b) (1.0 equiv) in 5 mL of dry NMP, N-methylmorpholine (NMM, 
3.0 equiv), and a catalytic amount of DMAP (0.05 equiv). After completion of the coupling, 
as monitored by HPLC, 25 mL of ether was added to the reaction mixture and the resulting 
emulsion centrifuged. The clear supernatant was decanted off, and the crude precipitate was 
purified by HPLC using 0.1% TFA–MeCN–water. Fractions containing pure phosphopeptide 
were combined and lyophilized to obtain pure products as white powders. Each was further 
dried over P2O5 chamber under vacuum at 37 °C before affinity measurements.53 Yields, 
HRMS, and HPLC retention times are reported in the Supporting Information.
General Procedure for Prodrug Formation..31,32
The appropriate amine, derived from a Boc-protected dipeptide as described above, was 
coupled with the building block 55a or b (1.0 equiv) in the presence of 3 mL of dry NMP, 
dry NMM (3.0 equiv), and a catalytic amount of DMAP (0.05 equiv). After completion, 
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checked by HPLC, the product was purified by RP-HPLC using acetonitrile–water (no 
TFA). The pure fractions were combined and lyophilized to obtain a white powder. Yields, 
HRMS, and HPLC retention times are reported in the Supporting Information.
Synthesis of βMpCinn-Tle-Sar-NMe(Ph), 21—To a stirred solution of Boc-Sar-OH 
(2.0 g, 10.6 mmol), N-methylaniline (1.2 g, 10.6 mmol), and HBTU (4.8 g, 12.7 mmol) in 
50 mL of dry CH2Cl2, DIEA (3.7 mL, 21.2 mmol) was added and the reaction stirred 
overnight. The mixture was diluted with an additional 50 mL of CH2Cl2, and the solution 
then washed with 5% HCl (2 × 30 mL) followed by 10% NaHCO3 (2 × 30 mL) and brine (1 
× 20 mL). The organic layer was dried (MgSO4) and evaporated to dryness under reduced 
pressure. The residue was treated with 10 mL of 95% TFA–CH2Cl2 for 1 h. The solvent was 
removed under vacuum and toluene (2 × 10 mL) was added and evaporated to get rid of 
residual TFA. The crude, foamlike material was treated with Boc-Tle-OH (1.2 equiv), 
HBTU (1.2 equiv), and DIEA (3.0 equiv) for 12 h in dry CH2Cl2 (50 mL). The solvent was 
evaporated in vacuo, and the residue was dissolved in EtOAc and washed with 5% HCl (3 × 
30 mL), 10% NaHCO3 (2 × 30 mL), and brine. After drying (MgSO4), filtration, and 
evaporation, the residue was treated with 95%TFA–DCM for 1 h. The solvent was 
concentrated under vacuum and then diluted with water and neutralized the aqueous solution 
with NH4OH and lyophilized to give an off-white foam. The amine was then treated with 
38b (1.0 equiv) in 5 mL of dry NMP, NMM (3.0 equiv), and a catalytic amount of DMAP 
(0.05 equiv). After completion of the coupling, as monitored by HPLC, 25 mL of ether was 
added to the reaction mixture and the resulting emulsion centrifuged. The clear supernatant 
was decanted off, and the crude precipitate was purified by HPLC using 0.1% TFA–
MeCN/H2O. Fractions containing pure phosphopeptide were combined and lyophilized to 
obtain pure phosphopeptide/phosphopeptidomimetic as a white powder. It was further dried 
over P2O5 chamber under vacuum at 37 °C before being used for affinity measurement. The 
yield and HRMS, and HPLC retention times are provided in the Supporting Information.
Synthesis of βMpCinn-Tle-Ala-NMe(Ph) (22) and βMpCinn-Tle-(Me)Ala-
NMe(Ph) (23)—These syntheses followed the same procedure as described for 21 starting 
with Boc-Ala-OH and Boc-N(Me)Ala-OH, respectively. Yields and HRMS and HPLC 
retention times are provided in the Supporting Information.
Fluorescence Polarization Assays
Peptides (200 µM) in “fluorescence polarization buffer” (FPB, 50 mM NaCl, 10 mM Hepes, 
1 mM Na4EDTA, 2 mM DTT, and 1% NP-40) were placed in 96-well plates, and serial 
dilutions were carried out in the same buffer on a Biomek 2000 liquid handling robot. 
Aliquots (50 µL) of a solution of STAT6 (480 nM) and 20 nM of FAM-Ala-pTyr-Lys-Pro-
Phe-Gln-Asp-Leu-Ile-NH2 in the same buffer were placed in wells of a second 96-well plate 
using the robot. To each well of the second plate was added 50 µL of the peptide solutions 
from the first plate. Fluorescence polarization was then read on a Tecan Infinite F200Pro 
plate reader. With use of Prizm 6, from GraphPad Software, Inc., the mP was plotted against 
the log of the peptide concentration and IC50 values were obtained from nonlinear regression 
analysis. Peptides were assayed in triplicate using three separate STAT6-probe preparations. 
IC50 values are reported as the mean of three IC50 values ± standard deviation.
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Inhibition of Stat6 Tyrosine641 Phosphorylation in Intact Cells
Beas-2B cells were seeded on 6-well plates at a density of 3.0 × 105 cells/well the day 
before treatment. Powdered prodrugs were dissolved in DMSO to obtain 5–10 µM stock 
solutions. Aliquots of the stocks were added to the cell cultures to reach the desired final 
concentrations of the prodrugs. Cultures were incubated with prodrugs for 2 h and 
stimulated with IL-4 or IL-13 (2 ng/mL) for 1 h. Cells were harvested, washed with ice-cold 
phosphate buffer saline (PBS), and lysed with cell lysis buffer (Cell Signaling, no. 9803), 
supplemented with phenylmethanesulfonylfluoride (PMSF) serine protease inhibitor. After 
incubation on ice for 10 min, cells were collected by scraping the dishes, and the resulting 
suspensions were centrifuged at 13200 rpm for 15 min at 4 °C. The supernatants were 
transferred to clean tubes, and aliquots (5 µL) were used to measure the concentration of 
proteins using the modified Lowry protein assay (BioRad) on a Tecan Infinite Pro 200 plate 
reader. Levels of pSTAT6 and total STAT6 proteins were estimated by Western blotting. 
Quantification of Western blotting band density was performed using ImageJ sofware.
Western Blotting
Aliquots of the whole cell lysate (15–30 µg proteins) were separated on a 10% SDS-PAGE 
polyacrylamide gel and transferred to PVDF membranes. The membranes were blocked 
with a 3% BSA solution in TBST (1× Tris-buffered saline, 0.1% Tween 20) and probed with 
phospho-Stat6 (Tyr641) antibody (Cell Signaling, no. 9361), followed by incubation with 
horseradish peroxidase conjugated secondary antibody (BioRad). Levels of pStat6 protein 
were detected with ECL detection reagents (GE Healthcare Life Science), capturing the 
resulting chemiluminescence signal on X-ray films. PVDF filters were then stripped with 
stripping buffer at rt for 30 min, blocked with 3% BSA, and probed with Stat6 antibody 
(Cell Signaling, no. 9362 or Santa Cruz, sc-374021) whose signal was detected as described 
above.
Effect of Prodrugs on Beas-2B Cell Proliferation
Effects of prodrugs on cell proliferation were determined by MTS assay. Beas-2B cells were 
seeded on a 96-well plate (2000 cells/well). Compounds were dissolved in DMSO to make 
10 mM stock solutions. Stocks were subjected to serial dilution in DMSO, and equal 
amounts of each dilution were added to the cultures. After incubation at 37 °C for 72 h, the 
culture medium was removed and a 1:5 MTS/PBS solution was added to each well. The dish 
was then incubated for an additional 1 h, and viable cells were estimated by measuring the 
optical density of the samples at 490 nm.
RT-PCR
RNA isolated from Beas-2B cells culture by Trizol (15596–026; Invitrogen, Grand Island, 
NY) was subjected to cDNA synthesis with TaqMan Reverse Transcription kit (N8080234; 
Applied Biosystems, Foster City, CA). Probes for CCL26 and β-actin were purchased from 
Applied Biosystems (Foster City, CA) to quantify relative expression using TaqMan Fast 
Universal PCR Master Mix (435189, Applied Biosystems, Foster City, CA) on a the 7500 
Real-Time PCR system (Applied Biosystems, Foster City, CA).
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Mice
C57BL/6J mice were purchased from Jackson Laboratories. Mice were housed in the SPF 
animal facility at the M. D. Anderson Cancer Center, and all animal experiments were 
approved by Institutional Animal Care and Use Committee.
CD4+ T Cells Activation and Immunoblot Analysis
CD4+ T cells from C57BL/6J mice were sorted by AutoMACS (Miltenyi Biotec) and 
activated with plate-bound anti-CD3 and/or anti-CD28 (eBioscience) alone or together with 
IL2, IL-6, or IL-4 (Peprotech) for 15 min. Cells were lysed in kinase assay lysis buffer 
supplemented with protease inhibitor cocktail (Roche) and phosphatase inhibitors (10 mM 
NaF and 1 mM Na3VO4). Protein concentration was determined by Bio-Rad Bradford 
protein assay, and equal amounts of protein were loaded for immunoblot analysis with 
antibodies against phospho-STAT1 (Tyr701), phospho-STAT3 (Ser727), phospho-STAT5 
(Tyr694), phosphor-STAT6 (Tyr641), STAT1, STAT3 (Cell Signaling), STAT5, and STAT6 
(Santa Cruz Biotechnology). Antimouse IgG-HRP and antirabbit IgG-HRP secondary 
antibodies were from Thermo scientific.
Molecular Modeling
A homology model of STAT6 was obtained from ModBase, a database of comparative 
protein structure models.37 The homology model is based on the template structure of 
STAT1 (PDB ID 1YVL, chain A), and residues 445–631, comprising the SH2 domain and 
part of the linker domain, were used. Using DINC,35,36 18a was docked to the SH2 domain 
of STAT6. The docked structure was simulated in explicit water using a molecular dynamics 
program in AMBER (version 11). Potentials for STAT6 were assigned with AMBER’s 
ff99SB force field, and those of 18a were assigned with GAFF force field. Point charges for 
18a were calculated using AM1-BCC charge model. The solvated complex was minimized 
in three rounds, with each round involving 1000 steps (10 steps of steepest descent 
minimization followed by 990 steps of conjugate gradient minimization). The solute (SH2 
domain of STAT6) was restrained/fixed in each round. The restraint weight was set to 5.0, 
2.0, and 0.05 (kcal/mol-Å2) in rounds 1, 2, and 3, respectively. The molecular dynamics 
protocol involved a temperature (300 K) equilibration step for 100 ps, a pressure 
equilibration step for 400 ps, followed by a production run of 20 ns at constant temperature 
and pressure. The time step used for the simulation was 2 fs, and the molecular dynamics 
trajectory was recorded every 1 ps. The structures of the complex derived from the last 10 ns 
of the trajectory were clustered using k-means (k = 5) clustering method, and the 
representative structure from the largest cluster was output as the model of 18a in complex 
with the STAT6 shown in Figure 3.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ABBREVIATIONS USED
DIEA diisopropylethylamine
DIPCDI diisopropylcarbodiimide
Fmoc 9-fluorenylmethoxycarbonyl
HBTU O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate
HOBt 1-hydroxybenzotriazole
IL-4 interleukin 4
IL-13 interleukin 13
JAK Janus kinase
pCinn 4-phosphoryloxycinnamide
βMpCinn β-methyl pCinn or [2E]3-(4-phosphoryloxyphenyl)-2-
butenamide
βMF2PmCinn [2E]3-[4-[(phosphinyl)difluoromethyl]phenyl]-2-
butenamide
POM pivaloyloxymethyl
SAR structure–activity relationship
SH2 domain Src homology 2 domain
STAT3 signal transducer and activator of transcription 3
STAT6 signal transducer and activator of transcription 6
TES triethylsilane
Th2 helper T cell type 2
TIS triisopropylsilane
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Figure 1. 
Schematic representation of the IL-4/JAK/STAT6 pathway. Note the IL-13 signals in an 
analogous manner using the IL-13R1/IL-4Rα coreceptor.
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Figure 2. 
Lead STAT6 inhibitor (from ref 33).
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Figure 3. 
Computed structure of 18a in complex with a homology model of STAT6. A representative 
complex from the largest cluster from the final 10 ns of a molecular dynamics simulation is 
shown (see Methods). (A) STAT6 (comprised of the linker and SH2 domains) is shown in 
surface representation with coloring according to amino acid hydrophobicity on Kyte–
Doolittle scale. (B) STAT6 is shown in surface representation with coloring according to 
APBS-based electrostatic potentials. (C) Intermolecular interaction diagram showing 
interactions between 18a and amino acids from the SH2 domain of STAT6. Structures in (A) 
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and (B) were drawn using Chimera software, (C) was drawn using Maestro/Schrödinger 
software, and (D) was rendered in PyMOL.
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Figure 4. 
Effect of structure on inhibition of pSTAT6 and cytotoxicity. Bease-2B immortalized human 
epithelial airway cells were treated with the prodrugs for 2 h and were then stimulated with 
IL-4 for 1 h. Cells were lysed, and total and phosphorylated STAT6 were estimated by 
Western blots. For each pair of gels, the top is pSTAT6 and the bottom is total STAT6. (A) 
Prodrugs with cinnamoyl pTyr mimcs. (B) Prodrugs with β-methyl pTyr mimics. (C) 
Graphic representation the integrals of the bands in (A) and (B). (D) Effect of prodrugs on 
viability of Beas-2B cells. Cells were treated with the prodrugs for 72 h and viability was 
measured with MTT assays.
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Figure 5. 
Prodrugs targeting the SH2 domain of STAT6 inhibit the expression of CCL26 mRNA. 
Beas-2B cells plated at 4 × 105 cells/well and incubated overnight in complete media, serum 
starved for 2 h, pretreated with drug for 2 h, stimulated with IL-13 overnight in serum free 
media, and total CCL26 mRNA was quantitated on cell lysates.
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Scheme 1. Synthesis of Bis-arylamide Inhibitors of STAT6a
aReagents and conditions: (a) EDC, 4-iodoaniline (for 34a) or aniline (for 34b), DCM, rt 12 
h; (b) Ph3Bi, Cu(OAc)2, TEA, DCM, 24 h; (c) (i) neat TFA, (ii) Boc-Tle-OH, HBTU, 
DIPEA, DCM rt 6 h; (d) neat TFA; (e) NMP, NMM, DMAP (cat), rt, 3 h; (f) (i) HBTU, 
DIPEA, DCM, 6 h, (ii) neat TFA, 1 h.
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Scheme 2. Synthesis of the Phosphotyrosine Mimic, 2-(di-tert-Butylphosphoryloxy)indole-2-
carboxylic Acida
aReagents and conditions: (a) TBDMS-Cl, NMM; (b) (i) (tBuO2)-PNEt2, 1H-tetrazole, (ii) 
tBuOOH; (c) H3O+.
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Scheme 3. Synthesis of C-Terminal Amide Substitutions
Reagents and conditions: (a) EDC, amine, DCM, rt, 12 h; (b) (i) neat TFA, (ii) HBTU, 
DIPEA, Boc-Tle-OH, (iii) neat TFA; (c) 38a or 38b, NMM, NMP, DMAP (cat).
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Scheme 4. Synthesis of Prolyl Surrogates with Amide Bond Replacementsa
aReagents and conditions: (a) NaH, PhCH2PPh3Br, THF; (b) (i) TFA, (ii) Boc-Tle-OH, 
HBTU, DIPEA, (ii) TFA; (c) NaH, PhCH2CH2CH2PPh3Br, THF; (d) H2, 10%Pd-C; (e) 
aniline, NaCNBH3, MeOH-AcOH; (g) formaldehyde (40% solution), NaCNBH3, MeOH–
AcOH.
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Scheme 5. Synthesis of Prodrug Analogues of 17 (See Chart 1 for Structures)
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Chart 1. 
Structures of Prodrug Analogues of 17
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Table 1
Affinity of Phosphopeptides Based on Tyr631 of IL-4Rα for STAT6
phosphopeptide IC50 (µM)
1 Ac-pTyr-Lys-Pro-Phe-Gln-Asp-Leu-Ile-NH2 1.8 ± 0.27
2 Ac-pTyr-Lys-Pro-Phe-Gln-Asp-Leu-NH2 2.4 ± 0.66
3 Ac-pTyr-Lys-Pro-Phe-Gln-Asp-NH2 4.5 ± 0.033
4 Ac-pTyr-Lys-Pro-Phe-Gln-NH2 4.2 ± 0.25
5 Ac-pTyr-Lys-Pro-Phe-NH2 6.1 ± 1.2
6 Ac-pTyr-Lys-Pro-NH2 5.2 ± 0.096
J Med Chem. Author manuscript; available in PMC 2016 November 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mandal et al. Page 37
Table 2
N-Terminal Derivatization and Amino Acid Substitutions at Position pY+1 in Tetrapeptide Xaa-pTyr-Ybb-
Pro-Phe-NH2
Xaa Ybb IC50 (µM)
5 CH3CO Lys 6.1 ± 1.2
7 CH3CO Tle 4.0 ± 1.2
8 CH3CO Nle 5.2 ± 1.2
9 CH3CO Ala 14.9 ± 1.6
10 PhCH2CH2CO Lys 8.1 ± 2.7
11 PhCH2CO Lys 4.1 ± 2.3
12 PhCO Lys 3.5 ± 0.78
13 PhCH=CHCO Lys 6.6 ± 0.37
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Table 3
Effect of Constrained pTyr Surrogates on the Affinity of Xaa-Lys-Pro-Phe-NH2
Xaa IC50(µM)
5 Ac-pTyr 6.1 ± 1.2
14 pCinn 8.6 ± 2.8
15 p-Indole 3.7 ± 0.052
16 p-Benzofuran 89.6 ± 1.5
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Table 4
Effect of Constrained pTyr Surrogates on Affinity for Phosphodipeptide R-Tle-Pro-N(Ph)(4-I-Phe) for STAT6
R IC50(µM)
18a pCinn
βMpCinn
0.044 ± 0.016
19a 0.028 ± 0.006
20 p-Indole 0.14 ± 0.06
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Table 5
Effect of C-Terminal Substitution on Affinity for STAT6
compd R1 R2 IC50 (µM)
18a H NPh(4-I-Ph) 0.044 ± 0.016
18b H NPh2 0.120 ± 0.04
18c H N(Me)Ph 0.87 ± 0.03
18d H NHPh 1.25 ± 0.34
19a Me NPh(4-I-Ph) 0.028 ± 0.006
19b Me NPh2 0.089 ± 0.01
19c Me N(Me)Ph 0.12 ± 0.03
19d Me NHPh 0.27 ± 0.07
19e Me NHCH2Ph 0.34 ± 0.07
19f Me NHCH2CH2Ph 0.25 ± 0.06
19g Me N(Me)(C6H11) 0.23 ± 0.14
19h Me N(Me)2 0.74 ± 0.34
19i Me N(Et)2 0.38 ± 0.09
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Table 6
Effect of Proline Replacements on βMpCinn-Tle-Xaa-N(Me)Ph
Xaa IC50 (µM)
19c proline 0.12 ± 0.03
21 sarcosine 0.27 ± 0.05
22 alanine 0.12 ± 0.016
23 N-methyl-alanine 0.48 ± 0.094
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Table 7
Effect of Modifications of the C-Terminal Amide Bond
# R IC50 (µM)
24 3.43 ± 0.95
25 0.54 ± 0.11
26 1.07 ± 0.17
27 0.41 ± 0.05
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